Decoy Therapeutics (FP11) Stock Statistics & Valuation Metrics
Total Valuation
Decoy Therapeutics has a market cap or net worth of EUR 2.28M. The enterprise value is -EUR 4.66T.
- Market Cap
- EUR 2.28M
- Enterprise Value
- -EUR 4.66T
Share Statistics
Decoy Therapeutics has 2,385,282 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,385,282
- Owned by Insiders
- 2.88%
- Owned by Institutions
- 0.68%
Financial Efficiency
Decoy Therapeutics’s return on equity (ROE) is -2.13 and return on invested capital (ROIC) is -214.20%.
- Return on Equity (ROE)
- -2.13
- Return on Assets (ROA)
- -1.13
- Return on Invested Capital (ROIC)
- -214.20%
- Return on Capital Employed (ROCE)
- -2.14
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.14M
- Employee Count
- 11
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Decoy Therapeutics is -0.04. Decoy Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.04
- PS Ratio
- 0.00
- PB Ratio
- 0.13
- Price to FCF
- -0.07
- Price to Operating Cash Flow
- -0.07
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Decoy Therapeutics had revenue of 0 and earned -12.52M in profits. Earnings per share was -25.99.
- Revenue
- 0
- Gross Profit
- -8.52M
- Operating Income
- -12.61M
- Pretax Income
- -12.52M
- Net Income
- -12.52M
- EBITDA
- -12.51M
- Earnings Per Share (EPS)
- -25.99
Cash Flow
In the last 12 months, operating cash flow was -8.32M and capital expenditures -42,426, giving a free cash flow of -8.37M billion.
- Operating Cash Flow
- -8.32M
- Free Cash Flow
- -8.37M
- Free Cash Flow per Share
- -15.73
Dividends & Yields
Decoy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1527.02%
- Earnings Yield
- -2637.13%
Stock Price Statistics
- Beta
- 1.09
- 52-Week Price Change
- -86.29%
- 50-Day Moving Average
- 5.23
- 200-Day Moving Average
- 5.38
- Relative Strength Index (RSI)
- 38.52
- Average Volume (3m)
- ―
Important Dates
Decoy Therapeutics upcoming earnings date is ―, TBA (Not Confirmed).
- Last Earnings Date
- Mar 30, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Decoy Therapeutics as a current ratio of 2.13, with Debt / Equity ratio of 0.00%
- Current Ratio
- 2.13
- Quick Ratio
- 2.13
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.86
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Decoy Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Decoy Therapeutics EV to EBITDA ratio is 0.54, with an EV/FCF ratio of 0.93.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.54
- EV to Free Cash Flow
- 0.93
- EV to Operating Cash Flow
- 0.93
Balance Sheet
Decoy Therapeutics has EUR 8.29M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 8.29M billion.
- Cash & Marketable Securities
- EUR 8.29M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 8.29M
- Net Cash Per Share
- EUR 3.48
- Tangible Book Value Per Share
- EUR 8.12
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Decoy Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 91.92%
